Engineered immune cells take aim at tough leukemia
NCT ID NCT06447987
Summary
This early-stage trial is testing a new version of CAR T-cell therapy for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back. The main goals are to find a safe dose and see if this approach can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.